Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Multiple Myeloma 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Burkitt Lymphoma 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 4tagraxofusp 3fludarabine phosphate 3fludarabine 3Methotrexate 3venetoclax 2Whole-Body Irradiation 2Vincristine 2Thiotepa 2Specimen Handling 2Rituximab 2Dexamethasone 2Cytarabine 2Calcium Dobesilate 2Azacitidine 2prednylidene 1merphos 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1azathiopurine 1auricularum 1X-Rays 1Tacrolimus 1Prednisone 1Mycophenolic Acid 1Methylprednisolone 1Mesna 1Mercaptopurine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Blastic Plasmacytoid Dendritic Cell Neoplasm × Medrol Veriderm × Clear all
NCT04216524 2026-04-14

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡